Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06863272CT.gov A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) | — | Recruiting | — | — | — |
NCT06661122CT.gov A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer | — | Recruiting | — | — | — |
NCT06473259CT.gov Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients | — | Recruiting | — | — | — |
NCT02915744CT.gov A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine | — | Completed | — | — | — |
NCT01917279CT.gov Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC | — | Unknown | — | — | — |
NCT01069081CT.gov Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00848718CT.gov A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003) | — | Completed | — | — | — |
NCT00519285CT.gov Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer | — | Completed | — | — | — |
NCT00377780CT.gov Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00377559CT.gov Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT00498797CT.gov E3-Hormone Refractory Prostrate Cancer Taxotere Combination | — | Completed | — | — | — |
NCT00190489CT.gov A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Docetaxel (this asset) | Merck Sharp & Dohme LLC | P3 | BB · 68 |
| Oxaliplatin | Ruijin Hospital | P4 | BBB |
| Fluorouracilum | Ruijin Hospital | P4 | BBB |
| Irinotecan | Eli Lilly and Company | P4 | BBB |
| Dexasone | Janssen Research & Development, LLC | P2 | BBB |
| Atezolizumab | UNC Lineberger Comprehensive Cancer Center | P2/3 | BB |
| Ipilimumab | 7 Hills Pharma, LLC | P3 | BB |
| Trastuzumab | City of Hope Medical Center | P3 | BB |
| Margetuximab | MacroGenics | P3 | BB |
+41 more in the Metastatic Neoplasm cohort
Other indications for Docetaxel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P4 | BBB · 73 |
| Pancreatic Adenocarcinoma | — | P2 | BBB · 72 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Docetaxel in Metastatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/docetaxel-metastatic-neoplasm-42580
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →